Livzon Pharmaceutical Group Inc (000513) — Cash Flow-to-Debt Ratio
Livzon Pharmaceutical Group Inc (000513) has a Cash Flow-to-Debt Ratio of 0.08x as of December 2025, meaning its operating cash flow of CN¥625.70 Million could theoretically repay 0% of its total liabilities (CN¥8.20 Billion) in one year. See Livzon Pharmaceutical Group Inc (000513) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Livzon Pharmaceutical Group Inc Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for Livzon Pharmaceutical Group Inc across 28 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Livzon Pharmaceutical Group Inc.
Annual Cash Flow-to-Debt Ratio for Livzon Pharmaceutical Group Inc (1998–2025)
Year-by-year debt coverage analysis for Livzon Pharmaceutical Group Inc. Check 000513 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.39x | CN¥3.18 Billion | CN¥8.20 Billion | ▲ +24.3% |
| 2024 | 0.31x | CN¥2.98 Billion | CN¥9.55 Billion | ▼ -1.3% |
| 2023 | 0.32x | CN¥3.25 Billion | CN¥10.28 Billion | ▲ +13.2% |
| 2022 | 0.28x | CN¥2.77 Billion | CN¥9.93 Billion | ▲ +18.3% |
| 2021 | 0.24x | CN¥1.90 Billion | CN¥8.06 Billion | ▼ -24.1% |
| 2020 | 0.31x | CN¥2.16 Billion | CN¥6.95 Billion | ▲ +0.3% |
| 2019 | 0.31x | CN¥1.77 Billion | CN¥5.70 Billion | ▲ +39.1% |
| 2018 | 0.22x | CN¥1.27 Billion | CN¥5.69 Billion | ▼ -21.0% |
| 2017 | 0.28x | CN¥1.32 Billion | CN¥4.66 Billion | ▼ -24.5% |
| 2016 | 0.37x | CN¥1.28 Billion | CN¥3.42 Billion | ▲ +31.6% |
| 2015 | 0.28x | CN¥927.79 Million | CN¥3.27 Billion | ▲ +27.4% |
| 2014 | 0.22x | CN¥717.39 Million | CN¥3.22 Billion | ▲ +50.0% |
| 2013 | 0.15x | CN¥439.99 Million | CN¥2.96 Billion | ▼ -38.6% |
| 2012 | 0.24x | CN¥593.96 Million | CN¥2.45 Billion | ▼ -45.6% |
| 2011 | 0.45x | CN¥708.20 Million | CN¥1.59 Billion | ▼ -28.1% |
| 2010 | 0.62x | CN¥633.30 Million | CN¥1.02 Billion | ▲ +12.5% |
| 2009 | 0.55x | CN¥494.88 Million | CN¥898.92 Million | ▲ +73.7% |
| 2008 | 0.32x | CN¥345.18 Million | CN¥1.09 Billion | ▲ +21.7% |
| 2007 | 0.26x | CN¥248.55 Million | CN¥954.80 Million | ▲ +23.7% |
| 2006 | 0.21x | CN¥226.46 Million | CN¥1.08 Billion | ▲ +20.8% |
| 2005 | 0.17x | CN¥161.07 Million | CN¥925.20 Million | ▼ -1.2% |
| 2004 | 0.18x | CN¥181.46 Million | CN¥1.03 Billion | ▼ -43.9% |
| 2003 | 0.31x | CN¥300.01 Million | CN¥954.70 Million | ▲ +6.9% |
| 2002 | 0.29x | CN¥213.65 Million | CN¥727.05 Million | ▲ +21.1% |
| 2001 | 0.24x | CN¥155.15 Million | CN¥639.37 Million | ▲ +266.2% |
| 2000 | 0.07x | CN¥38.52 Million | CN¥581.24 Million | ▼ -84.3% |
| 1999 | 0.42x | CN¥246.23 Million | CN¥583.95 Million | ▲ +1182.7% |
| 1998 | -0.04x | CN¥-18.21 Million | CN¥467.61 Million | — |